{"schema_version":"secwatch.filing_event.v1","accession":"0001808805-26-000027","form_type":"8-K","ticker":"NAUT","cik":"0001808805","company_name":"Nautilus Biotechnology, Inc.","filed_at":"2026-06-18T20:05:43+00:00","discovered_at":"2026-06-18T20:07:00.329497+00:00","generated_at":"2026-06-18T20:13:53.767467+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nautilus Biotechnology stockholders elect directors, ratify auditor, approve say-on-pay at 2026 annual meeting","bullets":["Elected Parag Mallick and Farzad Nazem as Class II directors with ~97% of votes cast (excluding broker non-votes).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026 with 84,937,704 votes for, 27,748 against.","Advisory say-on-pay approved with 69,994,022 votes for, 268,341 against; broker non-votes 14,708,618.","Stockholders favored a 1-year frequency for future say-on-pay votes (69,142,818 votes for 1-year).","Company will hold say-on-pay votes annually until at least the 2032 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001808805-26-000027","json":"https://secwatch.observer/filing/0001808805-26-000027.json","markdown":"https://secwatch.observer/filing/0001808805-26-000027.md","text":"https://secwatch.observer/filing/0001808805-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/0001808805-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/naut-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:13:53.767467+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"231bd517253cc6cbf913d1c248fc775f7a66deeb","claim":"Nautilus Biotechnology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-17 meeting.","evidence_excerpt":"The vote to approve, on an advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2025 (the “Say on Pay Vote”) was as follows: Votes For Votes Against Abstentions Broker Non-Votes 69,994,022 268,341 31,210 14,708,618","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/0001808805-26-000027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"b2871895fcf29901ab6f562025b049b84289015e","claim":"Nautilus Biotechnology, Inc. shareholders approved Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation at the 2026-06-17 meeting.","evidence_excerpt":"The vote to approve, on an advisory basis, the frequency of future Say on Pay Votes was as follows: 1-Year 2-Years 3-Years Abstentions 69,142,818 6,733 1,112,824 31,198","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/0001808805-26-000027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"cf962c315c3f18b7ee24592c616ecaa0ec0739dc","claim":"Nautilus Biotechnology, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-17 meeting.","evidence_excerpt":"The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions 84,937,704 27,748 36,739","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/0001808805-26-000027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"de2c4989d0c1dfdf3f1dba75afd95e1acb9f8f3d","claim":"Nautilus Biotechnology, Inc. shareholders approved Election of Class II Directors at the 2026-06-17 meeting.","evidence_excerpt":"The following nominees were elected to serve as Class II directors, each to hold office until the Company’s 2029 annual meeting of stockholders or until his respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Parag Mallick 67,882,439 2,411,134 14,708,618 Farzad Nazem 67,994,844 2,298,729 14,708,618","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808805/000180880526000027/0001808805-26-000027-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}